news
Arthritis drug baricitinib re-aimed to target diabetic kidney disease
Researchers have presented promising results from a clinical trial of the experimental drug baricitinib in people with diabetic kidney disease...
List view / Grid view
Baricitinib (Olumiant)
news
Asia-Pacific rheumatoid arthritis treatment market value will reach $7 billion by 2021
2 June 2015 | By Victoria White
The rheumatoid arthritis therapeutics market in the Asia-Pacific (APAC) region will expand in value from $5.6 billion in 2014 to an estimated $7 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 3.3%, according to business intelligence provider GBI Research.
news
Baricitinib superior to placebo in reducing rheumatoid arthritis disease activity in second Phase 3 study
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) today announce that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second consecutive Phase 3 trial in rheumatoid arthritis (RA). The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response…
news
Lilly and Incyte announce positive top-line results from Phase 3 trial of baricitinib in moderate to severe rheumatoid arthritis
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.
news
Lilly and Incyte’s oral JAK1 and JAK2 inhibitor, Baricitinib, showed positive results in Phase IIb study
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).
